APONVIE Drug Patent Profile

When do Aponvie patents expire, and when can generic versions of Aponvie launch?

Aponvie is a drug marketed by Heron Theraps Inc and is included in one NDA. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has nine patent family members in five countries.

The generic ingredient in APONVIE is aprepitant. There are twenty-six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the aprepitant profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aponvie

A generic version of APONVIE was approved as aprepitant by SANDOZ on September 24^th, 2012.

Summary for APONVIE

International Patents:	9
US Patents:	14
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	92
Patent Applications:	2,741
Drug Prices:	Drug price information for APONVIE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for APONVIE
What excipients (inactive ingredients) are in APONVIE?	APONVIE excipients list
DailyMed Link:	APONVIE at DailyMed

See drug prices for APONVIE

Pharmacology for APONVIE

Drug Class	Substance P/Neurokinin-1 Receptor Antagonist
Mechanism of Action	Cytochrome P450 2C9 Inducers Cytochrome P450 3A4 Inducers Cytochrome P450 3A4 Inhibitors Neurokinin 1 Antagonists

Paragraph IV (Patent) Challenges for APONVIE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
APONVIE	Intravenous Emulsion	aprepitant	32 mg/4.4 mL	216457	1	2023-11-07

US Patents and Regulatory Information for APONVIE

APONVIE is protected by fourteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Heron Theraps Inc	APONVIE	aprepitant	EMULSION;INTRAVENOUS	216457-001	Sep 16, 2022		RX	Yes	Yes
Heron Theraps Inc	APONVIE	aprepitant	EMULSION;INTRAVENOUS	216457-001	Sep 16, 2022		RX	Yes	Yes
Heron Theraps Inc	APONVIE	aprepitant	EMULSION;INTRAVENOUS	216457-001	Sep 16, 2022		RX	Yes	Yes
Heron Theraps Inc	APONVIE	aprepitant	EMULSION;INTRAVENOUS	216457-001	Sep 16, 2022		RX	Yes	Yes			Y
Heron Theraps Inc	APONVIE	aprepitant	EMULSION;INTRAVENOUS	216457-001	Sep 16, 2022		RX	Yes	Yes			Y

EU/EMA Drug Approvals for APONVIE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp & Dohme B.V.	Emend	aprepitant	EMEA/H/C/000527Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics).Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years.Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy.	Authorised	no	no	no	2003-11-11

International Patents for APONVIE

See the table below for patents covering APONVIE around the world.

Country	Patent Number	Title	Estimated Expiration
China	106852118	阿瑞吡坦乳剂制剂 (Emulson formulations of aprepitant)
European Patent Office	3193830	FORMULATIONS D'ÉMULSON D'APRÉPITANT (EMULSON FORMULATIONS OF APREPITANT)
Japan	2017533183	アプレピタントのエマルジョン製剤
Japan	2019196398	アプレピタントのエマルジョン製剤 (EMULSION FORMULATIONS OF APREPITANT)
Japan	2022092040	アプレピタントのエマルジョン製剤

Supplementary Protection Certificates for APONVIE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0734381	PA2004002	Lithuania		PRODCUT NAME: 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(TRIFLUORMETIL)FENIL]ETOKSI]-3-(4-FLUORFENIL)-4-MORFOLINIL]METIL]-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO./DATE: EU/1/03/262/001-006/20031111
0734381	SPC/GB04/011	United Kingdom		PRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113
0734381	PA2004002,C0734381	Lithuania		PRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111
0734381	3/2004	Austria		PRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111
0748320	08C0019	France		PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111

Last updated: June 2, 2026

APONVIE market dynamics and financial trajectory: demand drivers, pricing, payer coverage, and launch-to-revenue outlook

Executive summary

• APONVIE (active ingredient: apixaban; marketed as a brand anticoagulant in the US and other markets) has demand dynamics driven by atrial fibrillation stroke prevention and VTE treatment/secondary prevention, with utilization shaped by guideline adherence, competitive substitution to other oral anticoagulants (DOACs), and payer PA and step-therapy rules.
• Financial trajectory is dominated by (1) volume growth in guideline-directed indications, (2) erosion from DOAC competition and plan-level formulary placements, (3) rebate intensity and net-to-gross compression, and (4) patent and exclusivity expirations that affect long-term price durability.
• The near-term market outcome is less about medical differentiation and more about payer contracting, channel mix, and pharmacy-benefit manager (PBM) formulary status.

What is APONVIE and what market does it serve?

Featured snippet answer: APONVIE is used in anticoagulation for conditions including atrial fibrillation stroke prevention and venous thromboembolism (VTE) treatment and prevention; market demand tracks incident rates, guideline adoption, and payer formulary access.

Which indications drive demand for APONVIE?

A “market dynamics” view for apixaban products is indication-weighted. Demand is tied to:

• Atrial fibrillation (AF) with stroke risk stratification.
• DVT/PE treatment and prevention of recurrence.
• Post-surgical prophylaxis patterns (where applicable by label and geography).
• Longitudinal continuity because anticoagulation is often chronic.

How does line-of-therapy and setting affect uptake?

Uptake is shaped by where patients start:

• Hospital discharge to outpatient therapy after VTE.
• Outpatient initiation in AF during cardiology or primary care follow-up.
• Switching dynamics from warfarin and from other DOACs once clinicians and payers agree on formulary.

What patient volume and incidence factors matter most?

• Aging population and AF prevalence.
• Post-acute VTE incidence and recurrence rates.
• Clinician adherence to thrombosis prevention algorithms.
• Comorbidity burden that affects bleeding risk and DOAC selection.

How does APONVIE pricing and net-to-gross typically move in the US?

Featured snippet answer: For DOAC brands, pricing power is limited by PBM rebates and plan formulary position; net prices trend down over time, even if list price stays stable.

What drives net price and rebate intensity

For apixaban brands, net pricing is usually pressured by:

• Class competition among DOACs.
• Formulary tiering (preferred vs non-preferred).
• Contracted rebate structures tied to formulary placement and volume commitments.
• Generic and authorized generic leakage if exclusivity ends.

How payer design affects throughput

Payers influence realized revenue through:

• Prior authorization (PA) criteria tied to diagnosis and dosing.
• Quantity limits in early claim history and then periodic audit windows.
• Step therapy where payers prefer other DOACs or require documentation (renal function, prior therapy).

What does this mean for financial trajectory

Revenue growth can mask margin compression if:

• Gross-to-net widens due to rebates or clawbacks.
• Mix shifts toward lower-acquisition-cost channels or preferred-tier members with tighter net pricing.

Who are APONVIE’s competitive substitutes and how does competition reshape demand?

Featured snippet answer: APONVIE competes primarily with other DOACs and, in some segments, with warfarin; DOAC switching risk is high when formularies favor a cheaper agent.

Key competitive class effects

• DOAC-to-DOAC substitution: plan coverage decisions frequently determine which agent is “default.”
• Warfarin persistence: warfarin remains in patients with contraindications or complex valvular disease patterns.
• Brand-to-generic pressure: once an apixaban product faces generic competition in a given market, brand demand typically shifts quickly unless a payer still blocks substitution.

How does competitive intensity change by payer segment

• Commercial plans: stronger rebate-driven pressure; higher formulary churn.
• Medicare Advantage: PBM contracting strongly influences agent preference.
• Medicaid: coverage rules can accelerate generic substitution when available.

When does APONVIE lose exclusivity and what generic entry risks exist?

Featured snippet answer: Generic entry risk depends on the specific US and international reference product’s patent and exclusivity status; when exclusivity and key patents end, entry probability rises sharply.

Exclusivity and patent framework that governs entry

For anticoagulant brands, generic timing is often controlled by:

• Composition-of-matter patents.
• Formulation and polymorph/solid state patents.
• Method-of-use patents tied to indications.
• Manufacturing and process patents (if still active).
• Regulatory exclusivities (data exclusivity and any additional regulatory exclusivities, depending on jurisdiction).

Paragraph IV and litigation pathway

When generics file under Paragraph IV certifications (US), entry timing depends on:

• Initial 30-month stay outcomes.
• Settlement agreements and “no earlier than” dates.
• Court rulings on patent validity and infringement.

What patents protect APONVIE and how strong is the patent estate?

Featured snippet answer: The strength of an apixaban brand’s estate is usually concentrated in composition-of-matter and solid-state/formulation families, with downstream process and use patents adding incremental coverage depending on jurisdiction.

Patent estate structure that matters for business decisions

• Core composition coverage: drives long-term entry blocking.
• Formulation/solid-state: affects switches to alternative manufacturing or polymorphs.
• Method-of-use: less influential if claims are narrow and the main clinical practice aligns with non-covered uses.
• Manufacturing: can complicate supply if still active and tied to commercial-scale processes.

How to interpret “estate strength” in market terms

A “strong estate” usually correlates with:

• More limited generic launch windows.
• Higher expected settlement likelihood.
• Reduced probability of authorized generic suppression.

What is the Orange Book status of APONVIE?

Featured snippet answer: Orange Book listing content determines which patents and exclusivities attach to the FDA-approved NDA/ANDA reference product for the listed dosage forms and strengths.

Why Orange Book listing granularity matters

• Different NDCs can have different patent coverage.
• PA and dose-level contracting can change effective access even if “the drug” is broadly preferred.
• Claim scope across strengths can create staggered entry risk.

What formulation patents or delivery-system patents apply to APONVIE?

Featured snippet answer: For oral anticoagulants, formulation patents often target bioavailability stability, solid-state forms, and manufacturing controls rather than fundamentally new delivery systems.

Dose form coverage and commercial impact

• Strength-by-strength patent coverage affects which generics can enter first.
• If some strengths remain protected longer, brand retention can be extended in those subsegments.

Manufacturing and solid-state controls

• Polymorph control and particle size distributions can create practical barriers for generic bioequivalence if patents remain in force.
• Process patents can force licensing or design-around for generic entrants.

What method-of-use patents or clinical-use restrictions affect competition?

Featured snippet answer: Method-of-use patents can delay generic labeling expansion, but their real-world effect depends on claim breadth and clinical prescribing patterns.

How method-of-use coverage changes labeling and switching

• Narrow method claims may not stop substitution if the generic can market under non-covered use or if prescribers adopt guideline-approved alternative dosing patterns.
• Broad method claims can increase Paragraph IV risk and settlement leverage.

What APONVIE litigation affects generic launch timelines?

Featured snippet answer: Patent litigation timing and settlements control the start of generic sales in the US by shaping whether courts grant injunctions or parties agree to delayed entry.

What to track in litigation for revenue exposure

• Claim construction outcomes that narrow or broaden infringement.
• Validity findings linked to obviousness or anticipation.
• Settlement “at-risk” launch terms and authorized generic carve-outs.

Business impact of “at-risk” launches

• If a generic launches at risk and wins later, payers often switch quickly.
• If courts stay entry, brand revenue can hold longer, but net-to-gross may still compress due to competitive anticipation.

What is APONVIE’s FDA regulatory status and how does it affect market access?

Featured snippet answer: FDA approval status governs initial exclusivity and label scope; post-approval changes can affect substitution, dosing instructions, and payer coverage.

Label scope that governs payer behavior

• Dose and renal impairment wording.
• Switching guidance and discontinuation rules.
• Interactions and contraindication language.

How does APONVIE compare with competing apixaban brands and other DOACs?

Featured snippet answer: Within DOACs, outcomes depend less on pharmacology and more on payer placement, patient adherence, and price.

Side-by-side commercial drivers

• Formulary tier and copay positioning.
• Prior authorization friction.
• Persistence and adherence influenced by once- or twice-daily regimens and dosing complexity.

Where differentiation can show up commercially

• Subpopulation coverage where clinicians prefer apixaban based on bleeding risk perceptions.
• Health system procurement policies that standardize an agent.

What are the commercial milestones that typically determine revenue inflection for APONVIE?

Featured snippet answer: Revenue trajectory typically inflects after label expansions, major payer wins, and the outcome of exclusivity-linked generic entry.

High-impact business milestones

• Major formulary contracts (commercial and MA).
• Center for Medicare and Medicaid Services coverage or plan rules (MA).
• New indication approvals or dosing expansions.
• Launch of competitor promotions that force net price reductions.

Market forecast framework for APONVIE revenue exposure

Featured snippet answer: The dominant forecast variables are volume retention, net price erosion, and timing of generic entry.

Three scenario structure

• Base case: gradual net price decline with stable volume through payer access; moderate competitive pressure.
• Downside: payer tier downgrade and accelerated rebate increases, plus earlier-than-expected entry risks from exclusivity/patent erosion.
• Upside: sustained preferred placement, favorable contracting, and slower-to-materialize substitution.

Key takeaways

• APONVIE’s market dynamics follow DOAC class rules: payer contracting and formulary placement drive demand more than incremental clinical differentiation.
• Financial trajectory is typically a tug-of-war between volume stability and net-to-gross compression caused by rebate intensity and DOAC competition.
• Generic entry risk is tied to the Orange Book-listed patent and exclusivity structure and to any Paragraph IV litigation and settlement terms that define “no earlier than” launch dates.
• The most actionable revenue levers are payer tiering, PA burden, NDC-level patent coverage, and the timing and terms of any exclusivity-linked generic entry.

FAQs

1. How do PBM formulary tiers for apixaban affect APONVIE prescription volume after generic entry?
2. What do Orange Book patent expirations for different apixaban strengths imply for staggered generic launches?
3. How do prior authorization criteria change switching from APONVIE to competing DOACs in Medicare Advantage?
4. What settlement terms after Paragraph IV litigation most directly determine “launch at risk” timing for apixaban generics?
5. How do rebate structures and clawbacks typically move net price for DOAC brands across the first three years post-launch?

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Hatch-Waxman Act framework and Paragraph IV certification guidance materials. U.S. Food and Drug Administration.